Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

Name: Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
Published: 2010
License: Public Domain

The HIV Netherlands Australia Thailand Research Collaboration · 2010

ClinicalTrials.gov · Datasets · License: Public Domain · 2010

Open Source ↗

efficacy hiv-infections pharmacokinetics safety tuberculosis

hiv infections, tuberculosis, pharmacokinetics, safety, efficacy, lopinavir/ritonavir, hiv/tb, rifampicin containing anti-tuberculosis therapy, pharmacokinetics and safety of lopinavir/ritonavir with rifampicin containing anti-tuberculosis therapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

Related documents